BR112022008908A2 - Sistemas de permanência gástrica para administração de agentes ativos - Google Patents

Sistemas de permanência gástrica para administração de agentes ativos

Info

Publication number
BR112022008908A2
BR112022008908A2 BR112022008908A BR112022008908A BR112022008908A2 BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2 BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2
Authority
BR
Brazil
Prior art keywords
gastric
systems
disclosed
permanence
active agents
Prior art date
Application number
BR112022008908A
Other languages
English (en)
Portuguese (pt)
Inventor
KANASTY Rosemary
GRANT Tyler
Altreuter David
Weight Alisha
Moorthy Saumya
Tai Tammy
Jaramillo Montezco Juan
Schwarz Marlene
Hoon Yang Jung
TRAN Jeanne
Duan Michelle
Jing Jie
C Dufour David
Robert Waldemar Ryde Erik
Bhise Nupura
Holar Sonia
De La Torre Nicholas
Simses Craig
Beguin Estelle
Lai Erica
Peeke Erick
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of BR112022008908A2 publication Critical patent/BR112022008908A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022008908A 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos BR112022008908A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962933348P 2019-11-08 2019-11-08
US201962933210P 2019-11-08 2019-11-08
US201962933313P 2019-11-08 2019-11-08
US201962933211P 2019-11-08 2019-11-08
US201962933226P 2019-11-08 2019-11-08
US202062992075P 2020-03-19 2020-03-19
US202063052905P 2020-07-16 2020-07-16
PCT/US2020/059541 WO2021092491A1 (en) 2019-11-08 2020-11-06 Gastric residence systems for administration of active agents

Publications (1)

Publication Number Publication Date
BR112022008908A2 true BR112022008908A2 (pt) 2022-10-11

Family

ID=75849597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008908A BR112022008908A2 (pt) 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos

Country Status (10)

Country Link
US (1) US20220387311A1 (https=)
EP (1) EP4054545A4 (https=)
JP (1) JP2022553862A (https=)
CN (1) CN115003335A (https=)
AU (1) AU2020378438A1 (https=)
BR (1) BR112022008908A2 (https=)
CA (1) CA3160665A1 (https=)
IL (1) IL292849A (https=)
MX (1) MX2022005494A (https=)
WO (1) WO2021092491A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
JP7847119B2 (ja) 2020-07-29 2026-04-16 ザ・セカント・グループ・エルエルシー 架橋ポリ(セバシン酸グリセロール)を含む構造を含む形状誘導型制御放出および保持
US20240390270A1 (en) * 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone
AU2023209872A1 (en) * 2022-01-19 2024-08-01 Nortiva Bio, Inc. Dosage forms for gastric retention
CN115227879B (zh) * 2022-09-15 2023-01-06 北京天星博迈迪医疗器械有限公司 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法
US20240398701A1 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025042349A1 (en) * 2023-08-24 2025-02-27 Junion Therapeutics (Xiamen) Co., Ltd. A gastric residence article for oral administration
CN121752250A (zh) * 2023-08-24 2026-03-27 厦门君德医药科技有限公司 一种口服胃滞留物
WO2025148850A1 (zh) * 2024-01-09 2025-07-17 厦门君德医药科技有限公司 一种胃滞留装置
WO2025153071A1 (en) * 2024-01-18 2025-07-24 Junion Therapeutics (Xiamen) Co., Ltd. Gastric residence article for oral administration
WO2025195482A1 (zh) * 2024-03-22 2025-09-25 厦门君德医药科技有限公司 一种胃滞留装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US9622966B2 (en) * 2007-07-06 2017-04-18 Basf Corporation Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
AU2011285554C1 (en) * 2010-08-06 2016-05-12 Endoshape, Inc. Radiopaque shape memory polymers for medical devices
NZ727659A (en) * 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) * 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
CN109310639A (zh) * 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ,インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11793751B2 (en) * 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제

Also Published As

Publication number Publication date
AU2020378438A1 (en) 2022-06-02
WO2021092491A1 (en) 2021-05-14
US20220387311A1 (en) 2022-12-08
EP4054545A1 (en) 2022-09-14
IL292849A (en) 2022-07-01
CA3160665A1 (en) 2021-05-14
MX2022005494A (es) 2022-08-11
CN115003335A (zh) 2022-09-02
EP4054545A4 (en) 2024-02-14
JP2022553862A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
BR112022008908A2 (pt) Sistemas de permanência gástrica para administração de agentes ativos
WO2023141524A3 (en) Dosage forms for gastric retention
BR112019023985A2 (pt) sistema de autocorreção e componentes e métodos relacionados
Hébert et al. Transfusion threshold of 7 g per deciliter—the new normal
BR112021017288A2 (pt) Dispositivos, sistemas e métodos para liberar agentes terapêuticos em uma parede do estômago
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
Zhou et al. Drug stability and degradation studies
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112015018876A2 (pt) tampa de desinfecção para desinfetar uma extremidade de luer macho de um dispositivo de terapia de infusão
BR112012009185A2 (pt) realimentação e controle de dose de sistemas de descontaminação distribuída
BR112016024764A2 (pt) cateter dotado de porta ou encaixe luer fêmea com septo antimicrobiano
BR112017014390A2 (pt) cateter intravenoso de segurança com retenção à base de fricção e característica de deslocamento
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR122012017386B8 (pt) sistema de diálise
AU2019301069A8 (en) Mixing/administration system for vaccines and medicaments
MX2019007119A (es) Preparado oral del activador de glucocinasa y preparacion del mismo.
BR112015002755A8 (pt) Derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico e uso de derivados
ES486992A1 (es) Un procedimiento para la preparacion de un derivado de car- boestirilo
AR076716A1 (es) Modulo medicado con medicamento de premezcla
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
CO2019003873A2 (es) Sistemas y métodos para el suministro de medicamentos por relevos guiados
BR112022010339A2 (pt) Dispositivo de retenção de cateter
García Nano-and microparticles as drug carriers
CY1125856T1 (el) Ενδορρινικα σκευασματα επινεφρινης και μεθοδοι για τη θεραπεια ασθενειας

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]